MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

Core Insights - MetaVia Inc. has announced an expansion of its global patent protection for vanoglipel, a novel GPR119 agonist, with a portfolio of 48 granted and pending patents across multiple regions, providing protection until 2035 unless extended [1] - The patents cover the core compound, manufacturing processes, and potential therapeutic uses for serious metabolic and liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes (T2D) [1] - The CEO emphasized the importance of a strong intellectual property position to maximize the long-term value of vanoglipel, highlighting its broad therapeutic potential [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing vanoglipel (DA-1241) for MASH and DA-1726 for obesity [1] - Vanoglipel promotes the release of gut peptides that are beneficial for glucose and lipid metabolism, showing positive effects in preclinical studies and early-phase clinical trials [1] - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, demonstrating best-in-class potential for weight loss and glucose control in clinical trials [1] Clinical Development - Vanoglipel has shown efficacy in reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control in preclinical models of MASH and T2D [1] - In Phase 1a, 1b, and 2a trials, vanoglipel was well tolerated among participants, including healthy volunteers and those with T2D [1] - A Phase 2a clinical study indicated that vanoglipel has direct hepatic action alongside its glucose-lowering effects [1]